Scholarlink

<p>There are limited data on SARS-CoV-2 testing practices and positivity among children and adults affected by HIV. The Pediatric HIV/AIDS Cohort Study enrolls children, youth, and adults with perinatally-acquired HIV (PHIV), non-perinatally-acquired HIV (NPHIV), perinatal HIV exposure but uninfected (PHEU), and infants/children with PHEU across the United States and Puerto Rico. A Health Status Survey was developed and administered from April 2020 to November 2021 to assess cumulative incidence (%) of self-reported (1) SARS-CoV-2 testing uptake and results by HIV status, age, and pandemic period; (2) moderate and severe respiratory illness; and (3) hospitalization. At least one survey was completed for 2,289 participants (PHIV = 444, NPHIV = 644, PHEU = 1201) through November 2021; 62% identified as Black and 33% as Hispanic. Participants’ ages (years) ranged from 18–42 in PHIV, 19–57 in NPHIV, and &lt; 1–28 in PHEU. Among PHIV, NPHIV, and PHEU, respectively, 43%, 35%, and 16% reported SARS-CoV-2 testing; of these, 18%, 16%, and 11% testing positive. The proportion tested was similar by race, Hispanic ethnicity, education, and income. Overall, 4% (87/2289) were hospitalized for any illness. 8% (174/2289) reported a respiratory illness “worse than the common cold,” of whom 44% (76/174) reported SARS-CoV-2 testing, 49% (37/76) testing positive, and 13% (23/174) were hospitalized. The cumulative incidence of both SARS-CoV-2 positivity and severe COVID-19 disease as of November 2021 was lower than expected among persons affected by HIV. Testing access, uptake, and mitigation strategies in this population may explain these findings and inform strategies to prevent acquisition of respiratory viruses.</p><p><i>Trial Registration</i> Not applicable; this is not a clinical trial.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Low SARS-CoV-2 Positivity in a Large, Diverse US-Based Study of Persons Affected by HIV

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月24日

查看全文
  • Suzanne Siminski,
  • Brad Karalius,
  • Yanling Huo,
  • Kathleen Malee,
  • Renee Smith,
  • Tzy-Jyun Yao,
  • Deborah Kacanek,
  • Kathleen M. Powis,
  • Kunjal Patel,
  • Emily A. Barr,
  • Katherine Tassiopoulos,
  • Elizabeth J. McFarland,
  • Ellen G. Chadwick,
  • Nagamah Deygoo,
  • Denise L. Jacobson,
  • Emanuela Lela Lartey,
  • Rohit Kalra,
  • Mary Paul,
  • Shelley Buschur,
  • Chivon McMullen-Jackson,
  • Lynnette Harris,
  • Murli Purswani,
  • Martha Cavallo,
  • Mahboobullah Mirza Baig,
  • Alma Villegas,
  • Lisa Gaye Robinson,
  • Alan Bernegger,
  • Patricia Garvie,
  • Sandra K. Burchett,
  • Michelle E. Anderson,
  • Christine M. Salois,
  • Andrew Wiznia,
  • Ray Shaw,
  • Arry Dieudonne,
  • Juliette Johnson,
  • Karen Surowiec,
  • Janet S. Chen,
  • Taesha White,
  • Mitzie Grant,
  • Katherine Knapp,
  • Erick Odero,
  • Megan Wilkins,
  • Nicolas Rosario,
  • Heida Rios,
  • Vivian Olivera,
  • Margarita Silio,
  • Medea Gabriel,
  • Patricia Sirois,
  • Stephen A. Spector,
  • Megan Loughran,
  • Veronica Figueroa,
  • Sharon Nichols,
  • Carrie Chambers,
  • Christine Kwon,
  • Robin McEvoy,
  • Gwendolyn Scott,
  • Grace Alvarez,
  • Juan Caffroni,
  • Anai Cuadra

摘要

There are limited data on SARS-CoV-2 testing practices and positivity among children and adults affected by HIV. The Pediatric HIV/AIDS Cohort Study enrolls children, youth, and adults with perinatally-acquired HIV (PHIV), non-perinatally-acquired HIV (NPHIV), perinatal HIV exposure but uninfected (PHEU), and infants/children with PHEU across the United States and Puerto Rico. A Health Status Survey was developed and administered from April 2020 to November 2021 to assess cumulative incidence (%) of self-reported (1) SARS-CoV-2 testing uptake and results by HIV status, age, and pandemic period; (2) moderate and severe respiratory illness; and (3) hospitalization. At least one survey was completed for 2,289 participants (PHIV = 444, NPHIV = 644, PHEU = 1201) through November 2021; 62% identified as Black and 33% as Hispanic. Participants’ ages (years) ranged from 18–42 in PHIV, 19–57 in NPHIV, and < 1–28 in PHEU. Among PHIV, NPHIV, and PHEU, respectively, 43%, 35%, and 16% reported SARS-CoV-2 testing; of these, 18%, 16%, and 11% testing positive. The proportion tested was similar by race, Hispanic ethnicity, education, and income. Overall, 4% (87/2289) were hospitalized for any illness. 8% (174/2289) reported a respiratory illness “worse than the common cold,” of whom 44% (76/174) reported SARS-CoV-2 testing, 49% (37/76) testing positive, and 13% (23/174) were hospitalized. The cumulative incidence of both SARS-CoV-2 positivity and severe COVID-19 disease as of November 2021 was lower than expected among persons affected by HIV. Testing access, uptake, and mitigation strategies in this population may explain these findings and inform strategies to prevent acquisition of respiratory viruses.

Trial Registration Not applicable; this is not a clinical trial.